SC daratumumab approved in the EU as first treatment for high-risk SMM
Smoldering multiple myeloma (SMM) is an asymptomatic precursor of multiple myeloma, with high-risk patients facing a substantial likelihood of progression to symptomatic disease. Until now, there have been no approved treatment options for this patient population, and standard care has been limited to close monitoring. The recent European Commission (EC) approval of subcutaneous daratumumab, based on phase 3 AQUILA trial results, introduces the first licensed treatment for high-risk SMM and provides a new opportunity to delay or prevent progression to symptomatic disease.